---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-005063"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T00:37:12.840306+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience Q2 revenue $28.8M; adj. op. income up to $3.6M; guides FY23 $116-120M

## Summary
- Q2 revenue $28.8M (-1% YoY) as discontinued product headwinds ($1.6M) offset new product growth.
- GAAP op. income $0.8M (prior year included $4.9M litigation reversal); adj. op. income rose to $3.6M from $3.1M.
- Net loss $1.0M ($0.02 loss/share) vs. net income $2.4M; adjusted EPS $0.04 vs. $0.05.
- H1 cash from ops $5.4M; net debt reduced $5.4M YTD to $37.8M.
- FY2023 guidance: revenue $116-120M, gross margin ~60%, adj. EBITDA margin 15-17%, net leverage ~2x.

## SEC filing metadata
- accession: 0001171843-23-005063
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184323005063/0001171843-23-005063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184323005063/f8k_080823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-005063
- JSON: https://secwatch.observer/filing/0001171843-23-005063.json
- Plain text: https://secwatch.observer/filing/0001171843-23-005063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.